John Gambol, MD
Undersea and Hyperbaric Medicine · Placentia, CANPI 1255339826
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Smith+Nephew at 25.3% of the total. Reporting peaked in 2019 at $270 and has fallen 91.1% since, to $24 in 2025.
Across 53 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$305
- Urgo Medical North America, LLC$279
- Convatec Inc.$218
- KCI USA, Inc.$82
- Integra Lifesciences Corporation$75
- Tactile Systems Technology Inc$66
- plus $183 from 8 others
What the payments were for
- Food & beverage$1,207100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 20 | $305 |
| Urgo Medical North America, LLC | 4 | $279 |
| Convatec Inc. | 8 | $218 |
| KCI USA, Inc. | 5 | $82 |
| Integra Lifesciences Corporation | 4 | $75 |
| Tactile Systems Technology Inc | 4 | $66 |
| OVIK Health, LLC | 1 | $41 |
| Kerecis Limited | 1 | $30 |
| Solventum Corporation | 1 | $24 |
| Molnlycke Health Care US, LLC | 1 | $20 |
| Misonix Inc | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $12 |
How this compares
Too few undersea and hyperbaric medicine providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefpodoxime Proxetil | 33 | $4,467 |
| Gentamicin Sulfate | 69 | $3,489 |
| SsdSilver Sulfadiazine | 107 | $2,667 |
| Ciprofloxacin Hcl | 65 | $534 |
| Doxycycline Hyclate | 39 | $513 |
| Silver Sulfadiazine | 28 | $498 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 29 | $472 |
| Gabapentin | 20 | $397 |
| Fluconazole | 22 | $397 |
| Mupirocin | 28 | $335 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $186 |
| Triamcinolone Acetonide | 20 | $141 |
| Levofloxacin | 20 | $82 |
Paid to pharmacies, not to this prescriber.
Other undersea and hyperbaric medicine in Placentia
- Latisha Smith-ChaseRedding$5K
- Yoshinobu MifuneMurrieta$2K
- Sara SaltzsteinCamp Pendleton$1K
- Caesar AndersonSan Diego$1K
- Sandra HayesCoronado$764
- John MillingtonThousand Oaks$592
- William ToppenSan Diego$239
- John DeaconSanta Barbara$185
- Gary WillardCarlsbad$172
- Kenneth KellySan Diego$82
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.